Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Investor Presentation (June 2020)
24 slides from Cynata Therapeutics's investor presentation, June 2020
Slide 1: A Next Generation Stem Cell Therapeutics Company
A Next Generation Stem Cell Therapeutics Company Investor Presentation: Cynata Therapeutics Limited June 2020
Slide 2: Important Information
Important Information This presentation has been prepared by Cynata Therapeutics Limited. (“Cynata” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necess
Slide 3: Cynata is a clinical stage biotech with a highly scalable, proprietary platform
Cynata Therapeutics is a clinical stage biotech with a highly scalable, proprietary platform for developing stem cell therapeutics Our focus Financial information Share price (9-June-20) A$0.665 Utilise our proprietary CymerusTM platform technology to develop commercially scalable Shares on issue 11
Slide 4: Recent Developments: Optimising clinical programs
Recent Developments: Optimising clinical programs Ethics approval for Progressing clinical ✓ COVID-19 clinical trial ✓ FUJIFILM partnership driving GvHD Phase 2 ✓ development ▪ Accelerated planning and rapidly ▪ FUJIFILM endorsement via license ▪ Osteoarthritis 440 patient Phase 3 achieved ethics ap
Slide 5: MSCs have potential utility in complications arising from a COVID-19 infection
MSCs have potential utility in complications arising from a COVID-19 infection ▪ Increased global interest in the potential of MSCs to treat complications of COVID-19, representing external validation and early studies demonstrating potential utility1 ▪ COVID-19 is a respiratory virus that in some p
Slide 6: COVID-19 clinical development program underpinned by strong pre-clinical and clinical results
Cynata’s COVID-19 clinical development program is underpinned by strong pre- clinical and clinical results Cynata’s data supports utility of Cymerus MSCs, confirming that they: Compelling pre-clinical results in diseases which can arise from a COVID-19 infection: Significantly reduce levels of pro-i
Slide 7: MEND trial | Overview of Phase 2 clinical trial COVID-19 patients
MEND trial | Overview of Phase 2 clinical trial COVID-19 patients Target ▪ 24 adult patients with COVID-19 admitted to intensive care with compromised lung function, population which can ultimately progress to ARDS ▪ Respiratory distress (+ CRS and sepsis) represent significant unmet needs as conseq
Slide 8: Cymerus platform has potential applications across a wide range of diseases
Cynata's Cymerus platform has potential applications across a wide range of diseases Crohn’s Disease Others Osteoarthritis (funded by NHMRC) Fistula Coronary Artery Potential future Disease Phase 3 target areas ready Diabetic wounds Graft vs Host Disease (GvHD) ✓ Licensed Cymerus Pre- clinical Brain
Slide 9: Cynata is targeting significant market opportunities
Cynata is targeting significant market opportunities TARGET AREA TRIAL PHASE MARKET OPPORTUNITY Phase 3 Osteoarthritis (OA)1 US$11.6 bn ready Graft vs. Host Disease (GvHD)2 US$0.3 bn Phase 2 Critical limb ready ischemia (CLI)3 US$1.4 bn Acute respiratory distress syndrome (ARDS)4 US$2.5 bn COVID-19
Slide 10: Cynata is well placed amid expected MSC marketing approvals globally
Cynata is well placed amid expected MSC marketing approvals globally ~30 Phase 3 trials with MSC-based Cynata is uniquely placed in the therapies currently active MSC-based therapy market Graft vs. Host Disease (GvHD) Indications include: Many ongoing Phase 3 trials involve • Heart failure very comm
Slide 11: Conventional vs. Cynata's Cymerus MSC manufacturing process
Conventional vs. Cynata’s Cymerus MSC manufacturing process Current conventional MSC manufacturing process is impractical Cells donated Conventional process MSCs Cells from Cellular therapies MSC isolation MSC expansion multiple donors administered Substantial variability Limited quantity of MSCs La
Slide 12: Only platform able to produce commercial quantities of MSCs from a single source
Cynata has the only platform in the world able to produce commercial quantities of MSCs from a single source Conventional process Cymerus™ Significance for Cynata Continuous supply of new One donor, one time ✓ Lower cost; simplified logistics; highly Donors donors required (completed) consistent pro
Slide 13: World-first iPSC-derived cell therapy trial in steroid-resistant acute GvHD completed
World-first allogeneic iPSC-derived cell therapy clinical trial in steroid-resistant acute GvHD completed, with compelling results Phase 1 Clinical trial design Key clinical trial results ▪ Adults with steroid resistant All 53% 87% ≥87% acute graft-versus-host endpoints disease (GvHD) achieved Compl
Slide 14: Successful clinical data places Cynata in a strong position
Successful clinical data places Cynata in a strong position Successful study data Accelerates clinical development Demonstrating efficacy of our Unlocks multiple indications and an technology platform accelerated clinical development pathway ✓ Successful clinical results; all endpoints ▪ Successful
Slide 15: Executing on a clear scientific and commercial vision
Cynata is executing on a clear scientific and commercial vision and continually assesses pathways to optimise shareholder value Multiple options to create shareholder value case study Build value in platform independently (e.g. continue running clinical trials) ✓ Exclusive global licence in GvHD ✓ M
Slide 16: Investment Summary
Investment Summary ▪ Cymerus platform technology enables commercial-scale production of mesenchymal stem cells Scalable, globally ▪ Fully patented process overcomes multiple issues with today’s on-market solutions applicable technology ▪ Value of platform to a range of diseases demonstrated across c
Slide 17: Thank you for your attention
Thank you for your attention Cynata Therapeutics Limited Contact details: Level 3 62 Lygon Street [email protected] Carlton www.cynata.com Victoria 3053 Australia
Slide 18: Appendix
Appendix therapeutics
Slide 19: Globally experienced board and management team
Globally experienced board and management team Dr Paul Wotton Dr Ross Macdonald Dr Stewart Washer Dr Geoff Brooke Dr Darryl Maher Dr Kilian Kelly Chairman Managing Director / CEO Non-Exec Director Non-Exec Director Non-Exec Director Chief Operating Officer ▪ CEO, Obsidian ▪ 30 years’ experience ▪ 20
Slide 20: GvHD Phase 1 clinical trial results
GvHD Phase 1 clinical trial results Highly successful outcome, with majority of patients reporting a Complete Response from a devastating disease Phase 1 clinical trial data – all endpoints achieved1 Complete Response2 Overall Response3 Overall survival4 53% rate 87% rate ≥87% rate Patient data Lege
Slide 21: Critical Limb Ischemia | Overview of Cynata-led Phase 2 program
Critical Limb Ischemia | Overview of Cynata-led Phase 2 program 230,000 ~US$1.4B1 Addressable events per year Forecast annual global market sales Estimated market size Critical Limb ▪ MSC therapy for effective treatment of critical limb ischemia patients who are Ischemia (CLI) ineligible for revascu
Slide 22: Osteoarthritis | New Phase 3 program
Osteoarthritis | New Phase 3 program Funded by National Health and Medical Research Council 30,000,000 ~US$11.6B1 People in the USA affected by osteoarthritis Forecast global market opportunity by 2025 Estimated market size ▪ Assess the effect of Cymerus MSCs on clinical outcomes and knee joint stru
Slide 23: Pre-clinical studies | Ongoing value-creating program
Pre-clinical studies | Ongoing value-creating program Pre-clinical studies are intended to provide a rational basis for investigating the potential safety and efficacy of an experimental drug in particular disease indications Demonstrate • MSCs have already shown promising therapeutic potential in a
Slide 24: Pre-clinical studies | Existing target areas
Pre-clinical studies | Existing target areas Proof of Disease target Pre-clinical Global market Partner concept Key highlights area trials started opportunity* completed Study demonstrated effectiveness of Cymerus MSCs in sheep with ARDS in association US$2.5bn ARDS ✓ ✓ with the Prince Charles Hospi
Cynata Therapeutics — Investor Presentation (June 2020) on 6ix